| P50 | author | Gordon M. Cragg | Q116159652 |
| P2093 | author name string | John M Pezzuto | |
| P2860 | cites work | Homoharringtonine combined with cytarabine to treat chronic myelogenous leukemia in myeloid blast crisis and its impact on bone marrow CD34+CD7+ cells. | Q53241241 |
| | Five-year analysis of the prevention of colorectal sporadic adenomatous polyps trial. | Q54363102 |
| | Bioequivalence of Liposome-Entrapped Paclitaxel Easy-To-Use (LEP-ETU) formulation and paclitaxel in polyethoxylated castor oil: a randomized, two-period crossover study in patients with advanced cancer. | Q54512356 |
| | Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma. | Q55057216 |
| | A study of the bacterial community in the root system of the maytansine containing plant Putterlickia verrucosa | Q57003410 |
| | Antibody–drug conjugates for cancer: poised to deliver? | Q84974070 |
| | Fruit and vegetables and cancer risk | Q22251000 |
| | Caspase-1 inhibitors from an extremophilic fungus that target specific leukemia cell lines | Q24634265 |
| | The failure of cancer chemoprevention | Q26822900 |
| | Cancer wars: natural products strike back | Q26850074 |
| | From epoxomicin to carfilzomib: chemistry, biology, and medical outcomes | Q26864557 |
| | Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer | Q27013852 |
| | Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3 | Q27851579 |
| | Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study | Q28281843 |
| | Cancer chemopreventive activity of resveratrol, a natural product derived from grapes | Q28300555 |
| | PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study | Q28307838 |
| | Natural products as sources of new drugs over the 30 years from 1981 to 2010 | Q29616640 |
| | Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine | Q29616728 |
| | Chimeric antigen receptor T cells for sustained remissions in leukemia | Q29617588 |
| | Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes | Q33387020 |
| | Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. | Q33393879 |
| | Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study | Q33403865 |
| | Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma | Q33405119 |
| | Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma | Q33405181 |
| | Microbial genome mining for accelerated natural products discovery: is a renaissance in the making? | Q33804081 |
| | Generating a generation of proteasome inhibitors: from microbial fermentation to total synthesis of salinosporamide a (marizomib) and other salinosporamides | Q33836952 |
| | A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome | Q34035391 |
| | Long-term survival of participants in the prostate cancer prevention trial | Q34077860 |
| | Antibody conjugate therapeutics: challenges and potential | Q34224801 |
| | Pharmacokinetics and antitumor efficacy of XMT-1001, a novel, polymeric topoisomerase I inhibitor, in mice bearing HT-29 human colon carcinoma xenografts | Q34258910 |
| | Ingenol mebutate gel for actinic keratosis | Q34261250 |
| | Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials | Q34263106 |
| | The role of clofarabine in acute myeloid leukemia | Q34298181 |
| | First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies | Q34327123 |
| | Alpha-Tocopherol and beta-carotene supplements and lung cancer incidence in the alpha-tocopherol, beta-carotene cancer prevention study: effects of base-line characteristics and study compliance | Q34405945 |
| | Treatment of metastatic pancreatic adenocarcinoma: a review | Q34412863 |
| | Metagenomic small molecule discovery methods | Q34428178 |
| | Molecular basis of the Keap1-Nrf2 system. | Q34482586 |
| | Carfilzomib: a novel agent for multiple myeloma | Q38120296 |
| | From micrograms to grams: scale-up synthesis of eribulin mesylate | Q38125086 |
| | Bacterial symbionts in agricultural systems provide a strategic source for antibiotic discovery | Q38127133 |
| | Prodrug and nanomedicine approaches for the delivery of the camptothecin analogue SN38. | Q38127545 |
| | Novel taxanes | Q38174413 |
| | Diversity, abundance and natural products of marine sponge-associated actinomycetes. | Q38185243 |
| | New horizons for old drugs and drug leads | Q38185458 |
| | Omacetaxine mepesuccinate in the treatment of intractable chronic myeloid leukemia | Q38187115 |
| | Profile of sapacitabine: potential for the treatment of newly diagnosed acute myeloid leukemia in elderly patients | Q38213704 |
| | Antibody-drug conjugates—a new wave of cancer drugs | Q38279452 |
| | A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC). | Q38433690 |
| | Cabazitaxel: more than a new taxane for metastatic castrate-resistant prostate cancer? | Q39254676 |
| | Preclinical to clinical development of the novel camptothecin nanopharmaceutical CRLX101. | Q39575870 |
| | Multiple myeloma regression mediated by bruceantin | Q40590564 |
| | A Phase II study of Bruceantin (NSC-165, 563) in advanced malignant melanoma | Q40839231 |
| | Phase II trial of bruceantin in metastatic breast carcinoma. | Q40842922 |
| | Bathymodiolamides A and B, ceramide derivatives from a deep-sea hydrothermal vent invertebrate mussel, Bathymodiolus thermophilus | Q42721712 |
| | Population pharmacokinetic/pharmacodynamic modeling of drug-induced adverse effects of a novel homocamptothecin analog, elomotecan (BN80927), in a Phase I dose finding study in patients with advanced solid tumors | Q43737131 |
| | Brusatol-mediated induction of leukemic cell differentiation and G(1) arrest is associated with down-regulation of c-myc. | Q44194169 |
| | Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients | Q46367779 |
| | Multiple-pool cell lifespan models for neutropenia to assess the population pharmacodynamics of unbound paclitaxel from two formulations in cancer patients | Q46367785 |
| | Paclitaxel poliglumex, temozolomide, and radiation for newly diagnosed high-grade glioma: a Brown University Oncology Group Study. | Q48173556 |
| | The Nrf2-Keap1-ARE signaling pathway: The regulation and dual function of Nrf2 in cancer. | Q51145746 |
| | Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism | Q34534013 |
| | Antibody-drug conjugates: targeted drug delivery for cancer | Q34621670 |
| | Genexol inhibits primary tumour growth and metastases in gemcitabine-resistant pancreatic ductal adenocarcinoma | Q34625514 |
| | Screening and expression of genes from metagenomes | Q34709002 |
| | Recent advances in chemoprevention of cancer | Q34743443 |
| | Phase I/II clinical study on safety and antivascular effects of paclitaxel encapsulated in cationic liposomes for targeted therapy in advanced head and neck cancer | Q34754728 |
| | Risk-benefit profiles of women using tamoxifen for chemoprevention | Q34974865 |
| | Bacterial symbionts and natural products | Q35216091 |
| | Fruit, vegetables, and cancer prevention: a review of the epidemiological evidence | Q35413790 |
| | The pharmacology of resveratrol in animals and humans | Q35555258 |
| | Antitumor activity of bruceantin: an old drug with new promise | Q35676872 |
| | Update on taxane development: new analogs and new formulations | Q36470377 |
| | Trastuzumab-DM1: a clinical update of the novel antibody-drug conjugate for HER2-overexpressing breast cancer | Q36585636 |
| | The emerging role of the Nrf2-Keap1 signaling pathway in cancer | Q37271797 |
| | The use of higher dose clofarabine in adults with relapsed acute lymphoblastic leukemia | Q37406149 |
| | First line treatment of advanced non-small-cell lung cancer - specific focus on albumin bound paclitaxel | Q37419857 |
| | Novel taxane formulations and microtubule-binding agents in non-small-cell lung cancer | Q37442271 |
| | Potent antibody drug conjugates for cancer therapy | Q37469585 |
| | Impact of natural products on developing new anti-cancer agents | Q37473373 |
| | Marine-sourced anti-cancer and cancer pain control agents in clinical and late preclinical development | Q37566220 |
| | Metagenomic approaches to natural products from free-living and symbiotic organisms | Q37618576 |
| | Antibody-drug conjugate targets | Q37660495 |
| | Design of next-generation protein therapeutics | Q37773632 |
| | Biotechnological applications of psychrophiles | Q37775946 |
| | The protective effect of the Mediterranean diet: focus on cancer and cardiovascular risk | Q37831001 |
| | Natural products for cancer chemotherapy | Q37849845 |
| | Anticancer compounds derived from fungal endophytes: their importance and future challenges | Q37860171 |
| | Paclitaxel poliglumex for ovarian cancer | Q37862256 |
| | Biological potential and structure-activity relationships of most recently developed vascular disrupting agents: an overview of new derivatives of natural combretastatin a-4. | Q37886218 |
| | Cabazitaxel: a novel microtubule inhibitor | Q37902641 |
| | Venoms as a platform for human drugs: translating toxins into therapeutics | Q37937049 |
| | Nab-paclitaxel in the treatment of metastatic breast cancer: a comprehensive review | Q37960507 |
| | Clofarabine in the treatment of newly diagnosed acute myeloid leukemia in older adults | Q37968584 |
| | Endophytic fungi: novel sources of anticancer lead molecules | Q38012633 |
| | Liposomal paclitaxel formulations | Q38044520 |
| | Ingenol mebutate: a new option for actinic keratosis treatment | Q38077773 |
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | natural product | Q901227 |
| | chemotherapy | Q974135 |
| | neoplasm | Q1216998 |
| | phytochemicals | Q1639139 |
| | antineoplastic | Q2853144 |
| | biological products | Q67008917 |
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 41-59 | |
| P577 | publication date | 2015-12-17 | |
| P1433 | published in | Medical Principles and Practice | Q15759132 |
| P1476 | title | Natural Products as a Vital Source for the Discovery of Cancer Chemotherapeutic and Chemopreventive Agents | |
| P478 | volume | 25 Suppl 2 | |